Skip to main content
menu
Comparison Chart for FDA Authorized
COVID-19 Vaccines in the US

 

Pfizer/BioNTech

Moderna

J&J (Janssen)

Age restrictions

16 or older

18 or older

18 or older

Doses

2 doses, 21 days apart

2 doses, 28 days apart

1 dose

Efficacy-Overall*

95% (7 days after second dose)

94.1% (14 days after second dose)

 72% in US (28 days after dose)

Efficacy in Preventing Severe Disease*

90%

100%

87.6% in US

Efficacy in Preventing Death*

100%

100%

100%

What about the variants?

Developing booster

Developing booster

Adapting vaccine

Vaccine Type

mRNA

mRNA

Adenovirus vector

*in controlled experiments

Additional Information:

  • Real world conditions indicate 90% efficacy overall for mRNA vaccines (Pfizer and Moderna).
  • There have been 5814 reported breakthrough infections out of over 75 million vaccinated people who were more than 14 days after the 2nd dose (across all 3 vaccines).
    • 45% were over 60 years of age
    • 65% were women
    • 29% had no symptoms but tested positive
    • 2% (263) were hospitalized due to COVID-19
    • 1% (65) died

References

cq-text-component-placeholder
cq-text-component-placeholder